Skip to content

Open Label of Clinical Trial of Sulforaphane in Children With Autism

An Examination of Changes in Urinary Metabolites With Use of an Antioxidant Supplement, Sulforaphane, in School-aged Children With Autism

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02654743
Enrollment
21
Registered
2016-01-13
Start date
2016-01-31
Completion date
2016-09-30
Last updated
2019-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism

Brief summary

This is an open-label, 4-month study examining the effects of Sulforaphane (SF) on behavior in children with ASD and the correlation between behavior change and urinary metabolites. The goal is to determine a potential mechanism of action of SF in this population.

Detailed description

Sulforaphane (SF) is an isothiocyanate found in high levels in crucifers belonging to the family Brassicaceae (including broccoli, cabbage, cauliflower, brussels sprouts, Chinese cabbage and turnips). Many previous studies have documented that consumption of these vegetables is associated with a reduced risk of cancer (lung, breast, colon, rectum, and prostate).(Juge et al. 2007) The mechanism of action of these beneficial effects is believed to be due to the ability of SF to up-regulate genes that improve cellular response to oxidative stress, inflammation, DNA-damaging electrophiles, and radiation.(Singh et al. 2014) In a recent small, randomized controlled trial in children with autism, SF was shown to have beneficial effects on aberrant and social behavior.(Singh et al. 2014) The mechanism of action of this beneficial effect has not been established in children with ASD. Our primary goal is to examine changes in urinary metabolites in children with autism who receive SF to determine if changes in behavior are associated with changes in urinary metabolites.

Interventions

DIETARY_SUPPLEMENTSulforaphane

Children with ASD will receive Sulforaphane in this study

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 22 Years
Healthy volunteers
No

Inclusion criteria

* Male or female, enrolled at OHS, age 6-22 and with a diagnosis of ASD. * ASD diagnosis will be established by standard criteria (DSM-IV criteria and expert clinician review of medical records and child observation). * Written informed consent obtained from the subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion criteria

* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Design outcomes

Primary

MeasureTime frameDescription
Urinary metabolites3 monthUrine samples will be analyzed by lab and result will be provided
Behavior Measures3 monthsMeasuring behavior using ABC (Aberrant Behavior Checklist)- self reported 58 questions from 0-3 scale (0-not a problem; 3=severe problem)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026